The effect of N-acetylcysteine on blood pressure and markers of cardiovascular risk in non-diabetic patients with chronic kidney disease: A placebo-cotrolled, randomized, cross-over study

作者：Renke Marcin^*; Tylicki Leszek; Rutkowski Przemyslaw; Larczynski Wojciech; Neuwelt Alexander; Aleksandrowicz Ewa; Lysiak Szydlowska Wieslawa; Rutkowski Boleslaw

来源：Medical Science Monitor, 2010, 16(7): PI13-PI18.

• N-acetylcysteine
• blood pressure
• chronic kidney disease
• albuminuria
• homocyteine

Background: Cardiovascular complications in patients with chronic kidney disease (CKD) are frequent. They show increased cardiovascular mortality and morbidity attributable to accumulation of several risk factors; e. g., hypertension, oxidative stress and elevated plasma homocysteine concentration. Despite recent progress in their management, there is still no optimal therapy that can stop progression of CKD and decrease cardiovascular outcome in these patients. Antioxidants, e.g., N-acetylcysteine (NAC), have been suggested as a promising medicament in this field.
Material/Methods: In a placebo-controlled, randomized, two-period cross-over study we evaluated the influence of eight weeks of NAC therapy (1200 mg/day) added to pharmacological renin-angiotensin system blockade on ambulatory blood pressure and surrogate markers of cardiovascular risk and injury in 20 non-diabetic patients with albuminuria [30-915 mg per creatinine mg] and normal or slightly decreased kidney function [eGFR 61-163 ml/min]. After eight weeks run-in period during which the therapy using angiotensin converting enzyme inhibitors and/or angiotensin receptor blockers was settled, patients were randomly assigned to one of two treatment sequences: NAC/washout/placebo or placebo/washout/NAC.
Results: No significant changes in blood pressure, albuminuria and homocysteine plasma level were observed.
Conclusions: NAC had no effect on blood pressure and surrogate markers of cardiovascular injury in non-diabetic patients with CKD.

• 出版日期2010